Drug intelligence / Profile preview

Retico

Development stage: Unknown
Lead developer: AronPharma
Modality: Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

**Retico** is an AronPharma dietary nutraceutical for eye-health support, supplied as oral HPMC capsules. Its formulation contains the anthocyanin-standardized Oculoxin botanical extract blend from aronia, bilberry, and blue honeysuckle fruits, with rutin, folic acid, vitamin B6, and vitamin B12. The product is intended to support retinal function and ocular comfort in people exposed to prolonged screen-related blue-light exposure. AronPharma reports a completed clinical study evaluating Retico and a standardized extract mixture for protection against potential blue-light-associated retinal-cell damage; no specific clinical efficacy results were identified.

Brand names: Retico

Beyond the preview

Go deeper on Retico.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Retico.

Explore the full profile